Literature DB >> 11790163

Amyopathic dermatomyositis: a review by the Italian Group of Immunodermatology.

Marzia Caproni1, Carla Cardinali, Aurora Parodi, Barbara Giomi, Manuela Papini, Mario Vaccaro, Angelo Marzano, Clara De Simone, Marcello Fazio, Alfredo Rebora, Paolo Fabbri.   

Abstract

OBJECTIVE: To analyze the average age, sex distribution, duration of follow-up, clinical course, serologic abnormalities, and incidence of possibly associated malignancy in patients with amyopathic dermatomyositis.
DESIGN: Retrospective study.
SETTING: University hospitals. PATIENTS: Thirteen patients with amyopathic dermatomyositis.
RESULTS: The 13 patients represented 8.2% of 157 patients with dermatomyositis seen retrospectively in a 10-year period by the Italian Group of Immunodermatology of the Italian Society of Dermatology and Venereology. Gottron papules and sign and periungual telangiectasias were found in approximately 50% of cases (papules in 7 patients, Gottron sign and periungual telangiectasias in 6), while periorbital violaceous erythema was seen in 70% (9 patients). Arthralgias occurred in 2 patients and Raynaud phenomenon in 4. An elevated erythrocyte sedimentation rate was detected in 6 patients, hepatitis B virus antigen in 3, speckled antinuclear antibodies in 7, and anti-Ro and antimitochondrial antibodies in 1 case each. None of our patients had evidence of internal malignancy. Neither cardiopulmonary nor esophageal dysfunction was demonstrated. Electromyography showed a protopathic muscle abnormality in 3 patients. Muscle biopsy disclosed myositis and a neurogenic myopathy in another one.
CONCLUSIONS: Amyopathic dermatomyositis is a rare disease. So far, only 2 series of a few cases each have been reported. The "amyopathic" subset of dermatomyositis is peculiar in that its cutaneous lesions are predominant for long periods or even permanently, although they are indistinguishable from those of classic dermatomyositis. The minimal or absent muscle disease and the rarity of serum immunologic findings imply a favorable prognosis in white patients.

Entities:  

Mesh:

Year:  2002        PMID: 11790163     DOI: 10.1001/archderm.138.1.23

Source DB:  PubMed          Journal:  Arch Dermatol        ISSN: 0003-987X


  6 in total

1.  Interstitial lung disease in a patient with antisynthetase syndrome and no myositis.

Authors:  Sotiris C Plastiras; Fotini C Soliotis; Panayiotis Vlachoyiannopoulos; George E Tzelepis
Journal:  Clin Rheumatol       Date:  2005-11-23       Impact factor: 2.980

2.  Dermatomyositis: analysis of 109 patients surveyed at the Hospital das Clínicas (HCFMUSP), São Paulo, Brazil.

Authors:  Luciena Cegatto Martins Ortigosa; Vitor Manuel Silva dos Reis
Journal:  An Bras Dermatol       Date:  2014 Sep-Oct       Impact factor: 1.896

3.  Adult clinically amyopathic dermatomyositis with rapid progressive interstitial lung disease: a retrospective cohort study.

Authors:  Shuang Ye; Xiao-xiang Chen; Xiao-ye Lu; Mei-fang Wu; Yun Deng; Wen-qun Huang; Qiang Guo; Cheng-de Yang; Yue-ying Gu; Chun-de Bao; Shun-le Chen
Journal:  Clin Rheumatol       Date:  2007-02-17       Impact factor: 2.980

4.  Intravenous immunoglobulin therapy for refractory interstitial lung disease associated with polymyositis/dermatomyositis.

Authors:  Yuzo Suzuki; Hiroshi Hayakawa; Seiichi Miwa; Masahiro Shirai; Masato Fujii; Hitoshi Gemma; Takafumi Suda; Kingo Chida
Journal:  Lung       Date:  2009-04-22       Impact factor: 2.584

Review 5.  Pneumomediastinum and subcutaneous emphysema secondary to amyopathic dermatomyositis with cryptogenic organizing pneumonia in invasive breast cancer: a case report and review of literature.

Authors:  Sung Hwan Park; Yoon-Seup Kum; Kyung-Chan Kim; Jung-Yoon Choe; Sung-Hoon Park; Seong-Kyu Kim
Journal:  Rheumatol Int       Date:  2008-12-18       Impact factor: 2.631

Review 6.  The importance of including amyopathic dermatomyositis in the idiopathic inflammatory myositis spectrum.

Authors:  Elizabeth Ghazi; Richard D Sontheimer; Victoria P Werth
Journal:  Clin Exp Rheumatol       Date:  2012-11-22       Impact factor: 4.473

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.